Filament Health Corp. (FLHLF)
| Market Cap | 5.96M |
| Revenue (ttm) | 428.59K |
| Net Income (ttm) | -3.45M |
| Shares Out | 261.79M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Average Volume | 18,808 |
| Open | 0.0182 |
| Previous Close | 0.0182 |
| Day's Range | 0.0182 - 0.0228 |
| 52-Week Range | 0.0082 - 0.0471 |
| Beta | 1.05 |
| RSI | 54.38 |
| Earnings Date | Mar 31, 2025 |
About Filament Health
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquarter... [Read more]
Full Company ProfileFinancial Performance
In 2024, Filament Health's revenue was 616,678, a decrease of -71.06% compared to the previous year's 2.13 million. Losses were -4.97 million, -6.61% less than in 2023.
Financial numbers in CAD Financial StatementsNews
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications su...
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications The import was conducted in collaboration with the government of P...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications su...
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications SAN FR...
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky is also an advisor to Magdalena Biosciences , the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for...
Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the "Acquiror"), a shareholder of Filament Health Corp. ("Filament"), announces that on June 12, 2024, it ...
Filament Health Announces Annual General Meeting Voting Results
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2023) - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug de...
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet
Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health ...
Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications
Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health ...
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications Import of coca leaves was authorized by the Peruvian Health Autho...
What Will Catalyze Psychedelic Stocks?
Psychedelics being pulled into the mainstream by medical research. Filament Health CEO Benjamin Lightburn on clinical trials, microdosing and real revenue generation.
PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules
PharmAla contracted Filament subsidiary Psilo Scientific to manufacture the drug product for distribution to clinical trial customers and authorized patients PharmAla contracted Filament subsidiary Ps...
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adul...
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
New venture aligns with Jaguar's mental health Entheogen Therapeutics Initiative (ETI) and Filament's corporate mission to develop novel, natural prescription medicines from plants Magdalena Bioscienc...
Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial
SAN FRANCISCO--(BUSINESS WIRE)---- $FH #MentalHealth--Filament Health launches dosing in a ground-breaking FDA-approved psilocin clinical trial, first using naturally derived psychedelic drug candidat...
Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications
Drug Discovery Collaboration Will Leverage the Botanical Drug Development Expertise of Both Companies SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) and Filament Hea...